Table 1.
Baseline characteristics of the patients.
| All patients (n = 329) | Rechallenge(n=211) | Non-rechallenge(n=118) | p-value | |
|---|---|---|---|---|
| Age | ||||
| Median age (range), years | 62(56-68) | 62(57-69) | 62(55-67) | 0.116 |
| ≤60 | 133(40.4%) | 92(43.6%) | 41(34.7%) | |
| >60 | 196(59.6%) | 119(56.4%) | 77(65.3%) | |
| Sex | ||||
| Male | 298(90.6%) | 191(90.5%) | 107(90.7%) | 0.963 |
| Female | 31(9.4%) | 20(9.5%) | 11(9.3%) | |
| Smoking history | ||||
| Ever | 172(52.3%) | 106(50.2%) | 66(55.9%) | 0.321 |
| Never | 157(47.7%) | 105(49.8%) | 52(44.1%) | |
| Drinking history | ||||
| Ever | 172(52.3%) | 106(50.2%) | 66(55.9%) | 0.321 |
| Never | 157(47.7%) | 105(49.8%) | 52(44.1%) | |
| Best response to first line | ||||
| PR | 148(45.0%) | 100(47.4%) | 48(40.7%) | 0.362 |
| SD | 123(37.4%) | 73(34.6%) | 50(42.4%) | |
| PD | 58(17.6%) | 38(18.0%) | 20(16.9%) | |
| Liver metastasis | ||||
| Yes | 52(15.8%) | 34(16.1%) | 18(15.3%) | 0.838 |
| No | 277(84.2%) | 177(83.9%) | 100(84.7%) | |
| Lung metastasis | ||||
| Yes | 36(10.9%) | 22(10.4%) | 14(11.9%) | 0.689 |
| No | 293(89.1%) | 189(89.6%) | 104(88.1%) | |
| Bone metastasis | ||||
| Yes | 19(5.8%) | 13(6.2%) | 6(5.1%) | 0.688 |
| No | 310(94.2%) | 198(93.8%) | 112(94.9%) | |
| ECOG PS | ||||
| 0-1 | 317(96.4%) | 202(95.7%) | 115(97.5%) | 0.424 |
| 2 | 12(3.6%) | 9(4.3%) | 3(2.5%) | |
| Discontinuation reason | ||||
| Disease progression | 296(90.0%) | 191(90.5%) | 105(89.0%) | 0.893 |
| Toxicity | 6(1.8%) | 4(1.9%) | 2(1.7%) | |
| Others | 27(8.2%) | 16(7.6%) | 11(9.3%) | |
| Time to relapse after ICI-1 (months) | ||||
| <3 | 202(61.40%) | 130(61.61%) | 72(61.02%) | 0.915 |
| ≥3 | 127(38.60%) | 81(38.39%) | 46(38.98%) | |
| Radiotherapy | ||||
| Yes | 242(73.6%) | 151(71.6%) | 91(77.1%) | 0.273 |
| No | 87(26.4%) | 60(28.4%) | 27(22.9%) | |
| Treatment regimens of first-line | ||||
| ICIs monotherapy | 14(4.3%) | 7(3.3%) | 7(5.9%) | 0.442 |
| ICIs with Chemotherapy | 297(90.3%) | 194(91.9%) | 103(87.3%) | |
| ICIs with anti-VEGF | 4(1.2%) | 3(1.4%) | 1(0.8%) | |
| ICIs combined with chemotherapy plus anti-angiogenesis therapy | 14(4.3%) | 7(3.3%) | 7(5.9%) | |
| Treatment regimens of second-line | ||||
| ICIs monotherapy | 17(5.17%) | 17(8.06%) | 0(0%) | <0.001 |
| Chemotherapy with/without ICIs | 232(70.52%) | 137(64.93%) | 95(80.51%) | |
| Anti-VEGF with/without ICIs | 46(13.98%) | 37(17.54%) | 9(7.63%) | |
| Chemotherapy plus anti-angiogenesis therapy with/without ICIs | 34(10.33%) | 20(9.48%) | 14(11.86%) | |
| Clinical T stage | ||||
| 0-2 | 47(14.29%) | 31(14.69%) | 16(13.56%) | 0.778 |
| 3-4 | 282(85.71%) | 180(85.31%) | 102(86.44%) | |
| Clinical N stage | ||||
| 0-2 | 239(72.64%) | 157(74.41%) | 82(69.49%) | 0.337 |
| 3 | 90(27.36%) | 54(25.59%) | 36(30.51%) |
Abbreviations: ICI: immune checkpoint inhibitor; PR: partial response; SD: steady disease; PD: progressive disease; ECOG PS: Eastern Cooperative Oncology Group Performance Status